The price-to-earnings ratio has its supporters and detractors, but this simple statistic can be an easy way for investors to gauge how cheap an average stock is on the fly. For some stocks, however, the P/E ratio is a misleading statistic -- particularly when earnings betray a poor business model. With stocks' rise this year and earnings on the upswing, however, is the P/E ratio a suitable fit in the medical device industry, particularly as many device stocks have soared in 2013?
Using data compiled by stock screening site Finviz.com, here are three of the cheapest medical device stocks in the industry as sorted by the P/E ratio. Are these picks worth your investment -- or is this simple statistic hiding lagging financials and flailing companies? Motley Fool contributor Dan Carroll tells you what you need to know about the device industry's cheapest pickings below.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.�Click here now�to keep reading.
Top 10 Restaurant Stocks For 2015: TripAdvisor Inc (TRIP)
TripAdvisor, Inc. (TripAdvisor), incorporated on July 20, 2011, is an online travel research company, enabling users to plan and have a trip. TripAdvisor features reviews and advice on hotels, resorts, flights, vacation rentals, vacation packages and travel guides. TripAdvisor�� travel research platform features reviews and opinions from its community of travelers about destinations, accommodations (hotels, bed and breakfasts, specialty lodging and vacation rentals), restaurants and activities worldwide, through its TripAdvisor brand. TripAdvisor Websites include tripadvisor.com in the United States and versions of the Website in 30 countries, including in China under the brand daodao.com. TripAdvisor Websites also include links to the Websites of its travel advertisers allowing travelers to directly book their travel arrangements. In addition to the TripAdvisor brand, TripAdvisor, Inc. manages and operates Websites under 18 other travel media brands, providing travel planning resources across the travel sector. On December 20, 2011, Expedia, Inc. (Expedia) completed the spin-off of TripAdvisor, Inc. (TripAdvisor) to Expedia stockholders. TripAdvisor consists of the domestic and international operations previously associated with Expedia�� TripAdvisor Media Group. In October 2012, it acquired Wanderfly. In March 2013, it acquired Tiny Post (tinypost.co). In April 2013, the Company acquired Jetsetter.com and Gilt Travel Inc. In May 2013, TripAdvisor Inc acquired key technology and talent from CruiseWise Inc. In May 2013, TripAdvisor Inc acquired Guia de Apartamentos Niumba SL. In June 2013, the Company announced that it has acquired GateGuru.
TripAdvisor provides access worldwide to online travel agencies, including Expedia, Orbitz, Travelocity, hotels.com, Priceline and Booking.com. TripAdvisor Media Group offers travel suppliers graphical advertising and cost-per-click marketing platforms. TripAdvisor operates sites in 30 countries and in 21 languages, including sites in the United S! tates (http://www.tripadvisor.com), the United Kingdom (http://www.tripadvisor.co.uk), France (http://www.tripadvisor.fr), Ireland (http://www.tripadvisor.ie), Germany (http://www.tripadvisor.de), Italy (http://www.tripadvisor.it), Spain (http://www.tripadvisor.es), India (http://www.tripadvisor.in), Japan (http://www.tripadvisor.jp), Portugal and Brazil (http://www.tripadvisor.com.br), Sweden (http://www.tripadvisor.se), The Netherlands (http://www.tripadvisor.nl), Canada (http://www.tripadvisor.ca), Denmark (http://www.tripadvisor.dk), Turkey (http://www.tripadvisor.com.tr), Mexico (http://www.tripadvisor.com.mx), Norway (http://no.tripadvisor.com), Poland (http://pl.tripadvisor.com), Australia (http://www.tripadvisor.com.au), Singapore (http://www.tripadvisor.com.sg), Thailand (http://th.tripadvisor.com), Russia (http://www.tripadvisor.ru), Greece (http://www.tripadvisor.com.gr), Indonesia(http://www.tripadvisor.co.id), Argentina (www.tripadvisor.co.ar), Taiwan (www.tripadvisor.tw),Malaysia(http://www.tripadvisor.com.my), and Egypt (http://www.tripadvisor.com.eg). TripAdvisor also operates in China under the brand daodao.com (http://www.daodao.com) and Kuxun.cn (http://www.kuxun.cn).
Advisors' Opinion:- [By Holly LaFon] oundation bought 598,737 shares of TripAdvisor at an average cost of $27.04 in the fourth quarter. TripAdvisor Inc. is an online travel research company with a market cap of $3.78 billion; its shares were traded at around $30.7 with and P/S ratio of 5.93.
TripAdvisor actually spun off of Expedia (EXPE) in December 2011. Investors in Expedia received one share of TripAdvisor stock for every two shares of Expedia common stock they owned. This means that Larson, who held 750,000 shares of Expedia stock in the fourth quarter, received 375,000 shares and bought the remaining 151,263.
Expedia divided into two companies in order to unlock shareholder value. After the spin-off, Expedia, the largest travel company in the world, retains its travel agency brands. It is positioned to become a growth company in a $1 trillion travel market where people are flocking from offline to online trip planning. TripAdvisor will keep the reviews business, which contains 19 travel media and advertising brands.
As a stand-alone company, TripAdvisor reported fourth quarter revenues of $137.8 million, a 30% increase over fourth quarter 2010, and full-year revenues of $637.1 million, a 31% increase over full year 2010. It achieved earnings of $22 million, a 19% increase over fourth quarter 2010, and full-year 2011 net income of $177.7 million, a 28% increase over full-year 2010.
Though results were robust for TripAdvisors��first period as an independent company, it is susceptible to factors within the numerous markets with which it intersects. In 2012, for instance, higher search engine marketing costs caused it to forecast weak mid-double digit revenue growth, lower than 2011, and virtually flat earnings.
Diamond Foods (DMND)
Diamond Foods is a branded food company specializing in processing, marketing and distributing culinary, snack, in-shell and ingredient nuts under the Diamond of California and Emerald of California brands. It has a market cap of $
- [By Wallace Witkowski]
Other earnings highlights in the coming week include Dow components McDonald�� Corp. (MCD) , DuPont (DD) , AT&T Inc. (T) , and Procter & Gamble Co. (PG) . Notable S&P 500 companies include Halliburton Co. (HAL) , Netflix Inc. (NFLX) �, Amgen Inc. (AMGN) �, TripAdvisor Inc. (TRIP) �, Amazon.com Inc. (AMZN) �, Colgate-Palmolive Co. (CL) �, Ford Motor Co. (F) �, Dow Chemical Co. (DOW) �, and United Parcel Service Inc. (UPS) �
Top Long Term Stocks To Invest In 2014: Rvue Holdings Inc (RVUE)
rVue Holdings, Inc., incorporated on November 12, 2008, is an advertising technology company and operate rVue, a demand-side platform (DSP) for planning, buying and managing digital place-based networks and digital billboards and signage (DOOH) advertising. It provides media services, including an online, Internet based DSP that connects advertisers and/or advertising agencies with third party DOOH media or networks, that allows the advertiser to create a targeted advertising campaign and media plan, and negotiate that media plan simultaneously with all the third-party networks selected. The Company provides network services and receive fees under contract or on a monthly basis, from Accenture.
The Company's rVue DSP is accessible via the Internet. Through rVue, once an advertising campaign has been agreed to between the advertiser and the DOOH network owner, the DOOH networks receive the display advertising to be shown on their installed base of digital media displays. rVue allows programming and advertising to be customized for display in specific venues, at specific times, and for demographic targeting. It provides the tools for advertisers and advertising agencies to customize campaigns for details as specific as location, customer preference, product availability, current events and other needs. It provides Proof-of-Play analytics and the network statistics necessary to monitor advertising on the networks and assist in evaluating the performance or refinements required for an advertising campaign, in some cases real time. As of December 31, 2012, 182 networks, which consists approximately 770,000 screens and delivering over 250 million daily impressions representing 50 market areas accessible through rVue.
In connection with the Transaction, the Company acquired from Argo all of its assets related to the rVue business, which included all of the common stock of rVue, Inc. as well as software, contracts and technology. Such software and technology included the rVue DSP t! echnology and software as well as legacy rVue client and server software, which allows an end user to manage and operate a DOOH network. The client software is used to manage each screen or site and the server software is used to manage the client software. The Company�� services provide a digital advertising solution that streamlines the process of planning, buying and optimizing display advertising on DOOH display networks. rVue is designed to simplify the process of buying and selling digital display ads while connecting all the market players networks, advertisers, agencies, partners and developers from a unified platform to do business more efficiently and effectively.
Advisors' Opinion:- [By CRWE]
Today, RVUE has shed (-0.25%)�0.000 at $.199 with�5,000 shares in play thus far (ref. google finance Delayed: 9:39AM EDT July 17, 2013), but don�� let this get you down.
rVue Holdings, Inc. previously reported its financial results for the full year ended December 31, 2012.
Summary Results for the Full Year of 2012: Total revenue was $602,363 for fiscal 2012; down slightly from $643,483 in the prior year. Core Fees: This is the focus of our business and source of future growth. Core revenue for the years ended December 31, 2012 and 2011 were, $197,444 and $203,276, respectively.
Non-Core Fees: For the years ended December 31, 2012 and 2011 were $404,919 and $440,207, respectively. The decline was due to the end of a management relationship with Auto Nation. This trend will continue in 2013 as we focus more resources on core business efforts. In addition the Mattress Firm merged with Mattress Giant and we respectfully agree not to renew for 2013 (this represented approximately $230,000 in revenue). - [By CRWE]
Today, RVUE remains (0.00%) +0.000 at $.14 thus far (ref. google finance Delayed: 11:58AM EDT August 28, 2013).
rVue Holdings, Inc. previously reported its financial results for the quarter ended March, 31 2013.
Summary Results for First Quarter of 2013: Total revenue was $137.5K for the first fiscal quarter of 2013; up slightly from $131.5K the prior year.
Core Revenue: This is the focus of our business and source of future growth. Core revenue for the quarter ended March 31, 2013 was $79.3K up sharply (+63K) over Q1 2012 when it was $16.3K. Non-Core Revenue: For the quarters ended March 31, 2013 and 2012 were $58.2K and $115.2K, respectively. As stated earlier, the decline was due to the end of a management relationship with Auto Nation. This downward trend in non-core revenue is expected to continue through 2013 as we focus more resources on core business efforts. In addition, the Mattress Firm merged with Mattress Giant and we respectfully agreed not to renew for 2013.
Top Long Term Stocks To Invest In 2014: Intellipharmaceutics International Inc.(IPCI)
Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel or generic controlled and targeted release oral solid dosage drugs. The company?s patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of various existing and new pharmaceuticals. It has a pipeline of products in various stages of development in therapeutic areas, including neurology, cardiovascular, and gastrointestinal tract, pain, and infection. The company?s lead generic product under development includes generic Focalin XR (dexmethylphenidate hydrochloride), an extended-release capsule for the treatment of attention deficit hyperactivity disorder. Intellipharmaceutics has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. The company also has five generic products filed with the FDA, including a gene ric of Effexor XR (venlafaxine hydrochloride), an extended-release capsule for depression; Protonix (pantoprazole sodium), a delayed-release tablet for conditions associated with gastroesophageal disease; Glucophage XR (metformin hydrochloride), an extended-release tablet for managing type 2 diabetes; Seroquel XR (quetiapine fumarate), an extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; and Lamictal XR (lamotrigine), an extended-release tablet for the treatment of anti-convulsant for epilepsy. Its lead non-generic product under development is Rexista (oxycodone), an abuse- and alcohol-deterrent controlled-release oral oxycodone hydrochloride formulation for the relief of pain. The company also has a under late stage development product, such as Coreg CR (carvedilol phosphate), an extended-release capsule for hypertension and heart conditions. IntelliPharmaCeutics International Inc. was founded in 1998 and is based i n Toronto, Canada.
Advisors' Opinion:- [By Roberto Pedone]
A pharmaceutical player that's starting to trend within range of triggering a big breakout trade is IntelliPharmaCeutics (IPCI), which specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. This stock has been on fire over the last three months, with shares up a whopping 99%.
If you take a look at the chart for IntelliPharmaCeutics, you'll notice that this stock has been uptrending a bit over the last few weeks, with shares moving higher from its low f $3.12 to its recent high of $4.37 a share. During that uptrend, shares of IPCI have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of IPCI within range of triggering a big breakout trade above some key overhead resistance levels.
Traders should now look for long-biased trades in IPCI if it manages to break out some near-term overhead resistance levels at $4.37 to $4.62 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.31 million shares. If that breakout triggers soon, then IPCI will set up to re-test or possibly take out its 52-week high at $6.46 a share.
Traders can look to buy IPCI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $3.36 or at its 50-day moving average of $3.13 a share. One could also buy IPCI off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top Long Term Stocks To Invest In 2014: QUALCOMM Incorporated(QCOM)
QUALCOMM Incorporated engages in the development, design, manufacture, and marketing of digital wireless telecommunications products and services. The company operates in four segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), Qualcomm Wireless and Internet (QWI), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies code division multiple access (CDMA)-based integrated circuits and system software for wireless voice and data communications, multimedia functions and global positioning system products. The QTL segment grants licenses to use portions of its intellectual property portfolio comprising patent rights useful in the manufacture and sale of wireless products, such as products implementing cdmaOne, CDMA2000, WCDMA, CDMA TDD, GSM/GPRS/EDGE, and/or OFDMA standards and their derivatives The QWI segment consists of Qualcomm Internet Services that provides content enablement services for the wireless industry and pu sh-to-talk and other products and services for wireless network operators; Qualcomm Government Technologies, which offers development, hardware, and analytical services to the United States government agencies involving wireless communications technologies; Qualcomm Enterprise Services that provides satellite and terrestrial-based two-way data messaging, position reporting, wireless application services, and managed data services to transportation and logistics companies and other enterprise companies; and Firethorn, which builds and manages software applications that enable mobile commerce services. The QSI segment makes strategic investments to support the worldwide adoption of CDMA- and OFDMA-based technologies and services. QUALCOMM Incorporated primarily operates in China, South Korea, Taiwan, Japan, and the United States. The company was founded in 1985 and is based in San Diego, California.
Advisors' Opinion:- [By Ashraf Eassa]
Yes, Intel
Of course, the name that really fits this bill is Intel (NASDAQ: INTC ) . Sure, the investment community is gaga for names like Qualcomm (NASDAQ: QCOM ) , the company that powers the vast majority of handsets today -- the "Intel of smartphones," if you will -- and ARM, whose IP is in just about every smartphone/tablet today. - [By Keith Speights]
Qualcomm (NASDAQ: QCOM ) looks to be a winner if this prediction comes true. Its Qualcomm Life unit focuses on remote health management. The company's 2Net cloud platform for connecting biometric devices to remotely hosted applications opens the door to a wide array of possibilities for health-care providers to remotely monitor patients.
- [By Selena Maranjian]
Viking Global reduced its stake in lots of companies, including Qualcomm (NASDAQ: QCOM ) , a top player in the smartphone world, supplying iDevices and Android devices alike with its chips. Some promising moves by the company are its push into emerging markets and display technology, as well as its attention to the health-care industry and telemedicine. Qualcomm recently hiked its dividend by 40%, and its yield is now at 2.3%. Better still, its profit margins are fat, it's generating gobs of cash, and its revenue and earnings growth rates have been in the double digits for years now and have even been accelerating.
Top Long Term Stocks To Invest In 2014: iShares U.S. Medical Devices ETF (IHI)
iShares Dow Jones U.S. Medical Devices Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Medical Equipment Index (the Index). The Index measures the performance of the medical equipment sector of the United States equity market. The Index includes medical equipment companies, such as manufacturers and distributors of medical devices, such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, x-ray machines and other non-disposable medical devices.
The Fund will concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. Since all of the securities included in the Index are issued by companies in the medical equipment sector, the Fund will be concentrated in the medical equipment industry. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By John Udovich]
On Thursday, small cap medical device stock Integra Lifesciences Holdings Corp (NASDAQ: IART) jumped 9.90% after the FDA completed its inspection of the company's manufacturing facility which led to positive comments from analysts, meaning it might be time to take a look at its performance verses that of medical device ETFs like iShares Dow Jones US Medical Device ETF (NYSEARCA: IHI) and SPDR S&P Health Care Equipment ETF (NYSEARCA: XHE).
Top Long Term Stocks To Invest In 2014: Optimer Pharmaceuticals Inc.(OPTR)
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing hospital specialty products worldwide. It develops products that treat gastrointestinal infections and related diseases. The company provides two late-stage anti-infective product candidates, including Fidaxomicin, a narrow spectrum antibiotic for the treatment of Clostridium difficile-infection, which completed two Phase 3 trials; and Pruvel, a prodrug in the fluoroquinolone class of antibiotics, has completed two Phase 3 trials for the treatment of infectious diarrhea, including traveler?s diarrhea. It also develops product candidates using its proprietary technology Optimer One-Pot Synthesis, a computer-aided technology that enables the rapid synthesis of various proprietary molecules. In addition, the company?s other pipeline product candidates consist of CEM-101 (OP-1068), a macrolide and ketolide antibiotic, which is in Phase 2 trials for the treatment of upper and lower respiratory tract infections; and OPT-822/821, a novel carbohydrate-based cancer immunotherapy, is in Phase 2/3 trials for the treatment of metastatic breast cancer. It has collaborative agreements with Astellas Pharma Europe Ltd.; Par Pharmaceuticals, Inc.; Nippon Shinyaku, Co., Ltd.; Cempra Pharmaceuticals, Inc.; Memorial Sloan-Kettering Cancer Center; and The Scripps Research Institute. Optimer Pharmaceuticals, Inc. was founded in 1998 and is based in San Diego, California.
Advisors' Opinion:- [By Keith Speights]
"Bidness" is good (part 2)
Obagi isn't the only company for which "bidness" is good. Antibiotic maker�Optimer Pharmaceuticals (NASDAQ: OPTR ) shares soared 22% this week on talk of interest by multiple potential buyers.
No comments:
Post a Comment